Skip to main content
Premium Trial:

Request an Annual Quote

No New Concerns

No serious safety concerns have been identified in the first month of SARS-CoV-2 vaccinations in the US, Reuters reports.

The US Food and Drug Administration issued Emergency Use Authorizations for two SARS-CoV-2 vaccines, one from Pfizer and BioNTech and one from Moderna in December. A third vaccine from Johnson & Johnson is to be evaluated by the agency this month.

In the Center for Disease Control and Prevention's Morbidity and Mortality Weekly Report, researchers from CDC COVID-19 Response Team and the FDA examined additional safety data collected during the first month of wider SARS-CoV-2 vaccinations. In their sample of nearly 13.8 million vaccine doses, there were 6,994 reports of adverse reactions, 90 percent of which were not serious, such as headache or fatigue. They note that 113 deaths were reported in the population, but did not appear linked to vaccination. "These initial findings should provide reassurance to health care providers and to vaccine recipients and promote confidence in the safety of COVID-19 vaccines," the researchers add.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.